1-6 of 6
Audrey Kauffmann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 896: Predicting metastatic transcriptomes of patient tumors with deep learning

Gang Li, Evan Béal, Dean Sumner, Giorgio G. Galli, Viviana Cremasco, Joshua M. Korn, Frank Dondelinger, David Ruddy, Audrey Kauffmann, Slavica Dimitrieva
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 896.
https://doi.org/10.1158/1538-7445.AM2024-896
Published: 22 March 2024
View article titled, Abstract 896: Predicting metastatic transcriptomes of patient tumors with deep learning
Journal Articles

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201

Sébastien Jeay, Stéphane Ferretti, Philipp Holzer, Jeanette Fuchs, Emilie A. Chapeau, Markus Wartmann, Dario Sterker, Vincent Romanet, Masato Murakami, Grainne Kerr, Eric Y. Durand, Swann Gaulis, Marta Cortes-Cros, Stephan Ruetz, Therese-Marie Stachyra, Joerg Kallen, Pascal Furet, Jens Würthner, Nelson Guerreiro, Ensar Halilovic, Astrid Jullion, Audrey Kauffmann, Emil Kuriakose, Marion Wiesmann, Michael R. Jensen, Francesco Hofmann, William R. Sellers
Journal: Cancer Research
Series: Author Choice
Cancer Res (2018) 78 (21): 6257–6267.
https://doi.org/10.1158/0008-5472.CAN-18-0338
Published: 01 November 2018
View article titled, Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201
Open the PDF for Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201 in another window
Includes: Supplementary data
Journal Articles

Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition

Barbara Herkert, Audrey Kauffmann, Sandra Mollé, Christian Schnell, Thomas Ferrat, Hans Voshol, Janina Juengert, Hélène Erasimus, Grégory Marszalek, Malika Kazic-Legueux, Eric Billy, David Ruddy, Mark Stump, Daniel Guthy, Mitko Ristov, Keith Calkins, Sauveur-Michel Maira, William R. Sellers, Francesco Hofmann, Michael N. Hall, Saskia M. Brachmann
Journal: Cancer Research
Cancer Res (2016) 76 (2): 390–402.
https://doi.org/10.1158/0008-5472.CAN-14-3358
Published: 14 January 2016
View article titled, Maximizing the Efficacy of MAPK-Targeted Treatment in <em>PTEN</em><sup>LOF</sup><em>/BRAF</em><sup>MUT</sup> Melanoma through PI3K and IGF1R Inhibition
Open the PDF for Maximizing the Efficacy of MAPK-Targeted Treatment in <em>PTEN</em><sup>LOF</sup><em>/BRAF</em><sup>MUT</sup> Melanoma through PI3K and IGF1R Inhibition in another window
Includes: Supplementary data
Journal Articles

Abstract 854: Patient stratification strategies for NVP-BGJ398, a selective pan-FGFR inhibitor in phase I clinical trials

Diana Graus Porta, Vito Guagnano, Christelle Stamm, Simon Woehrle, Audrey Kauffmann, Yao Yao, Thomas Brümmendorf, Vincent Bordas, Mickaël Le Douget, Yun Zhang, Zhi Chen, Moriko Ito, Fang Li, John Monahan, Alex Gaither, Jason Borawski, Christopher J. Wilson, Kavitha Venkatesan, Francesco Hofmann, William Sellers
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 854.
https://doi.org/10.1158/1538-7445.AM2012-854
Published: 15 April 2012
View article titled, Abstract 854: Patient stratification strategies for NVP-BGJ398, a selective pan-FGFR inhibitor in phase I clinical trials
Journal Articles

Abstract 2332: The new protein FAM110B regulates the expression of E-cadherin and is involved in cell migration and invasion

Mehdi Naouar, Danièle Montaudon, Vincent Verbiest, Audrey Kauffmann, Audrey Laroche-Clary, Christophe Rey, Francesca De Giorgi, Philippe Pourquier
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 2332.
https://doi.org/10.1158/1538-7445.AM2011-2332
Published: 15 April 2011
View article titled, Abstract 2332: The new protein FAM110B regulates the expression of E-cadherin and is involved in cell migration and invasion
Journal Articles

Non amplified-MYCN stage 4 neuroblastoma: A genomic signature associated with good prognosis and spontaneous regression .

Jean Benard, Gilda Raguenez, Audrey Kauffmann, Alexander Valent, Hugues Ripoche, Virginie Joulin, Gisele Danglot, Marie-Jose Terrier-Lacombe, Philippe Dessen, Thomas Tursz, Vladimir Lazar, Dominique Valteau-Couanet
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 2955.
Published: 01 May 2007
View article titled, Non amplified-MYCN stage 4 neuroblastoma: A genomic signature associated with good prognosis and spontaneous regression .